Compare AbbVie Inc (ABBV) vs Vanguard Dividend Appreciation Index Fund ETF (VIG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Vanguard Dividend Appreciation Index Fund ETF — how do they compare? AbbVie Inc trades at $252.62 (market cap $449.91B), while Vanguard Dividend Appreciation Index Fund ETF trades at $237.6. The key difference: AbbVie Inc pays a 2.72% dividend while Vanguard Dividend Appreciation Index Fund ETF pays none. Which is the better fit depends on your goals.
| ABBV | VIG | |
|---|---|---|
Market Cap | $449.91B | — |
Sector | Health | — |
52-Week High | $261.07 | $239.03 |
52-Week Low | $184.85 | $204.09 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $253.61, down 0.45% on the day, with strong technical momentum showing bullish moving averages and key support at $253. The company reported Q1 2026 EPS of $2.65, beating expectations, while revenue growth is supported by Skyrizi and Rinvoq offsetting Humira declines. Analysts maintain a bullish consensus with 68% buy ratings and a $266.33 price target, representing 5% upside potential.
The outlook remains positive with robust immunology portfolio performance and dividend growth, though risks include patent cliffs in the 2030s and competitive pressures. Current valuation metrics appear elevated with P/E at 124.83, requiring sustained earnings growth to justify premium multiples. The stock offers income appeal with consistent dividend payments while navigating portfolio transition.
VIG trades at $238.88, up 0.11% with a bullish technical outlook supported by moving averages. The ETF focuses on U.S. companies with consistent dividend growth, maintaining a low 0.04% expense ratio. Recent news highlights its role in long-term wealth building through dividend compounding, though some analysts favor competitors like DGRO for momentum.
The outlook remains positive for income-focused investors seeking steady dividend growth, but risks include sector concentration in technology and competition from higher-yield alternatives. Wall Street sentiment is generally favorable, with the ETF's strategy appealing for passive income portfolios amid market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Vanguard Dividend Appreciation Index Fund ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that have a record of increasing dividends over time. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VIG →
